Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection.
about
HIV infection, aging, and immune function: implications for cancer risk and preventionMarkers of coagulation and inflammation often remain elevated in ART-treated HIV-infected patientsImmune restoration after antiretroviral therapy: the pitfalls of hasty or incomplete repairs.Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIVInflammation, coagulation and cardiovascular disease in HIV-infected individualsCardiovascular Complications of HIV in Endemic Countries.Enhanced effector function of CD8(+) T cells from healthy controls and HIV-infected patients occurs through thrombin activation of protease-activated receptor 1.Correlates of elevated interleukin-6 and C-reactive protein in persons with or at high risk for HCV and HIV infections.Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results.Platelet count kinetics following interruption of antiretroviral treatment.Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial.Immune activation and HIV persistence: implications for curative approaches to HIV infection.Monocyte-activation phenotypes are associated with biomarkers of inflammation and coagulation in chronic HIV infectionInitiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.Interleukin-6, high sensitivity C-reactive protein, and the development of type 2 diabetes among HIV-positive patients taking antiretroviral therapy.A prospective study of endothelial activation biomarkers, including plasma angiopoietin-1 and angiopoietin-2, in Kenyan women initiating antiretroviral therapyCardiovascular implications from untreated human immunodeficiency virus infection.Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir.The immunological and virological consequences of planned treatment interruptions in children with HIV infection.Factors associated with D-dimer levels in HIV-infected individuals.HIV-Associated Venous ThromboembolismCardiovascular manifestations of HIV infection in children.HIV infection is associated with decreased thrombin generationActivated platelet-T-cell conjugates in peripheral blood of patients with HIV infection: coupling coagulation/inflammation and T cellsLate Antiretroviral Therapy (ART) Initiation Is Associated with Long-Term Persistence of Systemic Inflammation and Metabolic Abnormalities.Elevated Biomarkers of Inflammation and Coagulation in Patients with HIV Are Associated with Higher Framingham and VACS Risk Index Scores.Inflammation predicts changes in high-density lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy.HIV and coronary arterial remodeling from the Multicenter AIDS Cohort Study (MACS)Myocardial Infarction, Stroke, and Mortality in cART-Treated HIV Patients on StatinsChanges in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.HIV replication, inflammation, and the effect of starting antiretroviral therapy on plasma asymmetric dimethylarginine, a novel marker of endothelial dysfunction.Relevance of Interleukin-6 and D-Dimer for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral Therapy.Adiposity influences airway wall thickness and the asthma phenotype of HIV-associated obstructive lung disease: a cross-sectional studyPotential cardiovascular disease risk markers among HIV-infected women initiating antiretroviral treatment.Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks.Effect of maraviroc on HIV disease progression-related biomarkers.Impact of immunodepression and moderate alcohol consumption on coronary and other arterial disease events in an 11-year cohort of HIV-infected patients on antiretroviral therapy.Biomarkers of inflammation in HIV-infected Peruvian men and women before and during suppressive antiretroviral therapy.Baseline kidney function as predictor of mortality and kidney disease progression in HIV-positive patients.Circulating levels of tissue factor microparticle procoagulant activity are reduced with antiretroviral therapy and are associated with persistent inflammation and coagulation activation among HIV-positive patients
P2860
Q27004165-E05074D9-82D4-45E9-988E-CB4CCE20AC05Q27024262-75331300-3900-43DD-8169-0C17CEC1A828Q27687272-62FA73BB-831E-46F4-9283-8B5CF7B95966Q28079826-55AF259A-3BE3-457F-ACEA-26DE60ECB747Q28483645-4A13C4A4-4664-447E-BE3C-FE36EBF304FFQ30244655-EE99CA20-1D5D-4289-8CAF-ABA595642DFDQ30532710-5BB2B436-257A-4867-9B42-3AF199994EF3Q30558355-A1B33E30-4CD4-4D2E-890F-7E79255F8E66Q31118978-1D471638-ECB6-40F8-9F31-C775DFD80252Q33403565-0EC6992A-7406-4C15-8052-9A510CD8D6C4Q33934080-C4B43CE3-184F-44F1-9F3B-5E2CF4212D64Q34351320-30A8D4D1-5E87-42B6-8137-E490801C9D43Q34396067-E1A4D9BE-937B-48FD-9B57-6BB7B4CDBE69Q34485916-8BA601E9-91C9-4133-8332-5E7B12E4BC2FQ34509012-7335CE38-5501-4422-9FF2-73D23657C23EQ34756452-C2AD350D-DEDF-49A6-9DBF-2A0AA10BE5FEQ34793193-5170E1D9-9A36-4427-BCB9-E726D9CE2A29Q35016964-7E5F3EF5-34F7-457E-99E3-3E3A4357A5F2Q35032305-34899604-05D9-4EF3-BD31-FA16FF53AF2CQ35120065-53EF8BF9-04E7-491F-9DE3-85B452D4356FQ35153652-4BA358D8-EF00-4B43-9659-EA055A900F6AQ35422302-B015D266-0B0A-448E-82AC-A601D8975505Q35845337-380FE44C-A53D-4BA4-BB90-4538EFF8C63CQ35853807-8A140E79-F526-45B4-BB98-788FA5F9B2D3Q35860942-E99DFBD5-323C-4826-B136-CC2F9A3E7362Q35862321-BDEAEC78-9D1B-46C4-9B32-88276677F581Q35873877-64303A45-EB3F-42DA-AFA4-5D261B299651Q35875428-A14D8FA6-FDA1-4FE5-BFCC-3D3028378991Q35894666-89476CCF-64BD-4496-8722-593F05C98A96Q35974422-6036AB84-1459-4910-B65E-2C6BE2949050Q35989740-B8B9F36B-82E8-44B9-9F58-8A16930BB882Q36015621-37B70FFE-6C9A-447B-B464-A5849BBD5E76Q36094376-88DB0792-AD7D-4997-A1C0-3918AD3B158DQ36104762-E1B6B32B-1FF2-428B-9FE5-C7BFE487950FQ36250357-7ADD0BB4-00B9-4A38-8263-A864F068516AQ36364075-4219D3C0-1B37-4716-BAA7-690DB6139989Q36496736-29DF5A90-0A69-4BCC-A51A-12B4798F5C09Q36775142-8751F310-0678-4850-9FF0-9761418BA658Q36852879-F7C1D6B7-0362-4D60-BDBA-C7FF399FCD21Q36930484-48082333-EC19-4FA0-BCBF-C1C45307C396
P2860
Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Changes in inflammatory and co ...... n patients with HIV infection.
@ast
Changes in inflammatory and co ...... n patients with HIV infection.
@en
Changes in inflammatory and co ...... n patients with HIV infection.
@nl
type
label
Changes in inflammatory and co ...... n patients with HIV infection.
@ast
Changes in inflammatory and co ...... n patients with HIV infection.
@en
Changes in inflammatory and co ...... n patients with HIV infection.
@nl
prefLabel
Changes in inflammatory and co ...... n patients with HIV infection.
@ast
Changes in inflammatory and co ...... n patients with HIV infection.
@en
Changes in inflammatory and co ...... n patients with HIV infection.
@nl
P2093
P2860
P50
P921
P1476
Changes in inflammatory and co ...... n patients with HIV infection.
@en
P2093
Bruno Ledergerber
Daniel Duprez
Daniel E Nixon
Fraser Drummond
INSIGHT SMART Study Group
Jacqueline Neuhaus
James D Neaton
Jason V Baker
Lewis H Kuller
Nicholas I Paton
P2860
P356
10.1097/QAI.0B013E3181F7F61A
P407
P577
2011-01-01T00:00:00Z